Back to Agenda
Session 8 Track 2B: Brave New World: Planning for Global Submissions in a Post-Disclosure World
Session Chair(s)
Robert Paarlberg, MS
Principal
Paarlberg & Associates LLC, United States
Learning Objective : At the conclusion of this session, participants should be able to:- Identify key areas within a company impacted by the ClinicalTrials.gov Final Rule and EMA Policy 0070
- Describe how disclosure/transparency requirements are impacting approaches to protocol and clinical study report writing
- Discuss potential legal implications that disclosure is having in the US and EU
- Describe how disclosure/transparency is impacting orphan/rare disease community
Speaker(s)
Speaker
Deborah Collyar
Patient Advocates In Research (PAIR), United States
President
Speaker
Mark Barnes, JD, LLM
Ropes & Gray, LLP, United States
Partner
Speaker
Kelly Vaillant
Vaillant Consulting, LLC, United States
President
Speaker
Rebecca Williams, PharmD, MPH
Essex, Part of Emmes Group, United States
Senior Clinical Trials Subject Matter Expert
Have an account?